We investigated the value of O-(2-18F-fluoroethyl)-l-tyrosine (18F-FET) PET for treatment
monitoring of immune checkpoint inhibition (ICI) or targeted therapy (TT) alone or in …

Purpose To evaluate whether 18 F-fluoroethyltyrosine (FET) PET can discriminate
progression from pseudoprogression of brain metastases in patients with non–small cell …

Introduction This pilot study aimed at exploring the utility of the proliferation tracer F-18
fluorothymidine (FLT) and positron-emission tomography (PET)/magnetic resonance …

In patients with brain metastasis, PET using labeled amino acids has gained clinical
importance, mainly regarding the differentiation of viable tumor tissue from treatment-related …

Background After focused high dose radiotherapy of brain metastases, differentiation
between tumor recurrence and radiation-induced lesions by conventional MRI is …

Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein-1 (PD-
1)/programmed cell death ligand-1 (PD-L1) frequently induces tumor response in metastatic …

Conventional MRI has important limitations when assessing for progression of disease
(POD) versus treatment-related changes (TRC) in patients with malignant brain tumors. We …

The advent of immunotherapy using immune checkpoint inhibitors (ICIs) and targeted
therapy (TT) has dramatically improved the prognosis of various cancer types. However …

Background Conventional MRI is the standard method to diagnose recurrence of brain
metastases after radiation. However, following radiation therapy, reactive transient blood …

The aim of this study was to investigate the potential of O-(2-18F-fluoroethyl)-l-tyrosine (18F-
FET) PET for differentiating local recurrent brain metastasis from radiation necrosis after …